References
- 1. Balaz S., Lukacova V.: Subcellular pharmacokinetics and its potential for library focusing. J Mol Graph Model 2002, 20, 479–490.
- 2. Blackwell T.: Veterinary Medical Ethics: Ethical question of the month - July 2002. Can Vet J 2002, 43, 749–750.
- 3. Bolton S., Bon C.: Pharmaceutical Statistics: Practical and Clinical Applications, Fourth Edition, Revised and Expanded, Informa Health Care, New York, 2003.
- 4. Bonora E., Willeit J., Kiechl, S., Oberhollenzer F., Egger G., Bonadonna R., Muggeo M.: Relationship between insulin and carotid atherosclerosis in the general population. The Bruneck Study. Stroke 1997, 6, 1147–1152.
- 5. EC, Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin. 2010R0037 - EN - 12.12.2010 - 002.001 - 1 Amended by Commission regulations in 2010 European Commission. 2010; pp. 1–76.
- 6. EC, Technical Guidance Document in Support of Commission Directive 93/67/EEC on Risk Assessment for New Notified Substances and Commission Regulation (EC) No 1488/94 On Risk Assessment for Existing Substances. Part II. European Commission, 1996.
- 7. EMEA, Committee for Medicinal Products for Human Use (CHMP), Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. 2006c.
- 8. FAO, Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL. 2004.
- 9. FDA, Environmental Impact Assessments (EIA’s) For Veterinary Medicinal Products (VMP’s) - Phase II VICH Gl38 Final Guidance. 2006b, pp. 1–37.
- 10. FDA, Guidance for Industry Environmental Assessment of Human Drug and Biologics Applications. 1998, pp. 1–41.
- 11. Grabowski T., Jaroszewski J.J., Piotrowski W.: Correlations between no observed effect level and selected parameters of the chemical structure for veterinary drugs. Toxicol In Vitro 2010, 24, 953–959.
- 12. Grabowski T., Jaroszewski J.J., Piotrowski W., Feder M.: Qualitative structure residue relationship analysis in the determination of the maximum residue limit of veterinary drugs. Chemosphere 2012, 87, 312–318.
- 13. HC, Policy on Extra-Label Drug Use (ELDU) in food producing animals. http://www.hc-sc.gc.ca/dhp–mps/vet/label–etiquet/pol_eldu–umdde–eng.php (Accessed April 7, 2008).
- 14. Kubinyi H.: QSAR: Hansch analysis and related approaches. In: Methods and principles, published by Wiley–VCH. Weinheim, 1993, Vol. 1, pp. 20–190.
- 15. Leardi R. Nature-inspired methods in chemometrics: genetic algorithms and artificial neural networks. 1st ed., Elsevier, Amsterdam, 2003.
- 16. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J.: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46, 3–26.
- 17. Machatha S.G., Yalkowsky S.H.: Comparison of the octanol/water partition coefficients calculated by ClogP, ACDlogP and KowWin to experimentally determined values. Int J Pharm 2005, 294, 185–192.
- 18. Martinez M.N., Amidon G.L.: A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002, 42, 620–643.
- 19. Mattisson I., Wirfält E., Andrén C., Gullberg B., Berglund G.:. Dietary fat intake-food sources and dietary correlates in the Malmö Diet and Cancer cohort. Public Health Nutr 2003, 6, 559–569.
- 20. OECD, 117 OECD Guideline for Testing of Chemicals. 1989, pp. 1–11.
- 21. OECD, OECD Environment Health and Safety Publications Series on Testing and Assessment No. 58, Report on the Regulatory Uses and Applications in OECD Member Countries of (Quantitative) Structure-Activity Relationship ((Q)SAR) Models in the Assessment of New and Existing Chemicals. 2006, pp. 1–79.
- 22. OECD, OECD Environment Health and Safety Publications Series on Testing and Assessment No. 69, Guidance Document on the Validation of (Quantitative) Structure-Activity Relationships ((Q)SAR) MODELS. 2007, pp. 1–154.
- 23. OECD, The report from the expert group on (Quantitative) Structure–Activity Relationships ((Q)SARs) on the principles for the validation of (Q)SARs. 2004, pp. 11–198.
- 24. Palm K., Luthman K., Artursson P.: An alternative explanation for the low membrane permeability of highly lipophilic drugs. Eur J Pharm Sci 1996, 4, 195–195.
- 25. Peng Y.; Taylor J. M., Yu B. A marginal regression model for multivariate failure time data with a surviving fraction. Lifetime Data Anal 2007, 13, 351–369.
- 26. Piatkowska M., Jedziniak P., Zmudzki J.: Review: Residues of veterinary medicinal products and coccidiostats in eggs – causes, control and results of surveillance program in Poland. Pol J Vet Sci 2012, 15, 803–812.
- 27. Pratim R.P., Paul S., Mitra I., Roy K.: On two novel parameters for validation of predictive QSAR models. Molecules 2009, 14, 1660–1701.
- 28. Tetko I.V., Gasteiger J., Todeschini R., Mauri A., Livingstone D., Ertl P., Palyulin V.A., Radchenko E.V., Zefirov N.S., Makarenko A.S., Tanchuk V.Y., Prokopenko V.V.: Virtual computational chemistry laboratory - design and description. J Comput Aided Mol Des 2005, 19, 453–463.
- 29. Williams S.G., Taylor J.M., Liu N., Tra Y., Duchesne G.M., Kestin L.L., Martinez A., Pratt G.R., Sandler H.: Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68, 24–33.
- 30. Wils P., Warnery A., Phung-Ba V. Legrain S., Scherman D.: High lipophilicity decreases drug transport across intestinal epithelial cells. J Pharmacol Exp Ther 1994, 269, 654–658.
- 31. Yu B., Tiwari R.C., Cronin K.A., Feuer E.J.: Cure fraction estimation from the mixture cure models for grouped survival data. Stat Med 2004, 15, 1713–1747.